AGTC News and Press, Applied Genetic Technologies Corporation From 02/04/21

Article reflects Company’s leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC),...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announce...

Applied Genetic Technologies (AGTC) has priced its public offering of 16,741,573 common shares, together with accompanying warrants to purchase 8,370,786 common shares.The combined offering price $4.45 and expected gross proceeds are ~$74.5M.The five years warrants have an exercise price...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...

Gene therapy company Applied Genetic Technologies' (AGTC) shares jump ~19% in after market trade after it posts promising additional data from its ongoing ACHMB3 and ACHMA3 clinical trials in patients with achromatopsia ((ACHM)), an inherited retinal disease.The ...

Applied Genetic Technologies (AGTC) has announced to offer common stock shares and pre-funded warrants, in an underwritten public offering.Volume, price are yet to be determined.Net proceeds will be used to fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigm...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announc...

-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints- -Company plans longer term follow-up, dosing of younger pediatric patients, and addition of new brain im...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced th...

Applied Genetic (AGTC): Q1 GAAP EPS of -$0.60 misses by $0.08.Cash, cash equivalents and investments of $66.6M.Press Release For further details see: Applied Genetic EPS misses by $0.08